We are live on ! Find out more
ATRS

Antares Pharma, Inc.
ATRS

Delisted

ATRS was delisted on the 23rd of May, 2022.

Back to rankings

97 hedge funds and large institutions have $171M invested in Antares Pharma, Inc. in 2013 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 47 increasing their positions, 18 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 4

174% more call options, than puts

Call options by funds: $1.01M | Put options by funds: $368K

161% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 18

11% more funds holding

Funds holding: 87 → 97 (+10)

10% less capital invested

Capital invested by funds: $190M → $171M (-$18.9M)

Holders
97
Holders Change
+10
Holders Change %
+11.49%
% of All Funds
3.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
47
Reduced
18
Closed
4
Calls
$1.01M
Puts
$368K
Net Calls
+$640K
Net Calls Change
+$2.16M

Top Buyers

Rank Fund Capital Flow
1
HCM
Harvey Capital Management
Florida
+$2.31M
2
BFA
BlackRock Fund Advisors
California
+$1.67M
3
BIT
BlackRock Institutional Trust
California
+$1.01M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$964K
5
WHI
William Harris Investors
Illinois
+$546K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$21.1M
2
DM
Deerfield Management
New York
-$3.26M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$944K
4
UOC
UBS O'Connor
Illinois
-$913K
5
TCIM
TIAA CREF Investment Management
New York
-$666K
Name Holding Trade Value Shares
Change 		Change in
Stake
CA
76
Corrado Advisors
New Jersey
$56K +$60.1K +13,750 New
LPL Financial
77
LPL Financial
California
$55K +$4.37K +1,000 +9%
Citadel Advisors
78
Citadel Advisors
Florida
$52K -$195K -44,744 -78%
CAM
79
Capstone Asset Management
Texas
$49K – – –
D.E. Shaw & Co
80
D.E. Shaw & Co
New York
$48K +$51.6K +11,809 New
Prudential Financial
81
Prudential Financial
New Jersey
$47K +$1.75K +400 +4%
GC
82
Guggenheim Capital
Illinois
$44K +$3.13K +716 +7%
WAM
83
World Asset Management
Michigan
$42K – – –
Comerica Bank
84
Comerica Bank
Texas
$42K +$651 +149 +1%
CCMG
85
Clark Capital Management Group
Pennsylvania
$41K – – –
AL
86
Airain Ltd
Guernsey
$41K +$44K +10,085 New
Royal Bank of Canada
87
Royal Bank of Canada
Ontario, Canada
$34K +$14.3K +3,277 +62%
Ameriprise
88
Ameriprise
Minnesota
$29K – – –
Creative Planning
89
Creative Planning
Kansas
$22K +$11.6K +2,646 +98%
BlackRock
90
BlackRock
New York
$20K – – –
Barclays
91
Barclays
United Kingdom
$17K -$7.01K -1,606 -28%
BG
92
BlackRock Group
United Kingdom
$11K – – –
Bank of Montreal
93
Bank of Montreal
Ontario, Canada
$10K – – –
CA
94
CapWealth Advisors
Tennessee
$7K +$7.86K +1,800 New
LTFS
95
Ladenburg Thalmann Financial Services
Florida
$2K – – –
Manulife (Manufacturers Life Insurance)
96
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$377 -$14.9K -3,416 -4%
BP
97
Ballentine Partners
Massachusetts
– -$499K -120,000 Closed
U
98
UBS
Switzerland
– -$244K -55,837 Closed
BWM
99
Baystate Wealth Management
Massachusetts
– -$6K -1,397 Closed
DADC
100
D.A. Davidson & Co
Montana
– -$4K -1,000 Closed
1 2 3
4

ATRS Hedge Fund Activity: Q3 2013 in Review

97 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q3 2013, worth a combined $171M — down 9.9% from $190M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new ATRS positions and 4 closed out — a net gain of 10 holders — while 47 added to existing stakes and 18 trimmed.

The largest buyer was Harvey Capital Management, opening a new position worth an estimated $2.31M. The largest seller was OrbiMed, cutting an estimated $21.1M.

  • 97 institutional investors held Antares Pharma, Inc. (ATRS) as of Q3 2013, up from 87 in Q2 2013.
  • Funds reported $171M of Antares Pharma, Inc. stock for Q3 2013, down 9.9% quarter-over-quarter.
  • 14 funds opened new Antares Pharma, Inc. positions in Q3 2013 and 4 closed out, a net change of +10 holders.
  • The largest Antares Pharma, Inc. buyer in Q3 2013 was Harvey Capital Management, an estimated $2.31M added.
  • The largest Antares Pharma, Inc. seller in Q3 2013 was OrbiMed, an estimated $21.1M sold.

Based on aggregated 13F filings for Q3 2013.